GlassScriptPhysician profile
Carl C Mayberry
NPI 1538241567
$17,521.29
in general payments reported to CMS, 2019-2025
35 companies · $2,407 in 2025
The $2,407 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,607 · 2022: $4,166 · 2023: $5,847 · 2024: $2,494 · 2025: $2,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,678 · Travel and Lodging: $1,566 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,677.61 |
| Travel and Lodging | $1,565.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,505.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $5,859.85 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Gilead Sciences, INC. | $1,882.64 | 2021-2025 | Biktarvy |
| Abbvie INC. | $1,747.29 | 2021-2025 | |
| Theratechnologies INC. | $1,403.21 | 2021-2025 | Trogarzo, Egrifta, Egrifta Sv |
| Napo Pharmaceuticals INC | $850.38 | 2021-2025 | Mytesi |
| Janssen Biotech, INC. | $825.27 | 2021-2023 | Symtuza |
| Emd Serono, INC. | $820.67 | 2021-2025 | Serostim |
| Shionogi INC | $783.39 | 2021-2025 | Fetroja |
| Viiv Healthcare Company | $766.09 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Paratek Pharmaceuticals, INC. | $705.46 | 2021-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $493.88 | 2021-2025 | Xerava, Zevtera, Xacduro |
| Axsome Therapeutics, INC. | $193.49 | 2023-2024 | Sunosi |
| Janssen Products, LP | $184.99 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.34 | 2021-2024 | Trulance, Xifaxan |
| Amarin Pharma, INC. | $112.26 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $91.82 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $79.30 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Ferring Pharmaceuticals INC. | $68.13 | 2022-2023 | Rebyota |
| Eisai INC. | $67.28 | 2025 | |
| Pharming Healthcare, INC. | $63.69 | 2024-2025 | Ruconest |
| Novo Nordisk INC | $42.86 | 2024 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $37.40 | 2021-2022 | |
| Antares Pharma, INC. | $33.26 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Invivyd INC | $28.65 | 2024 | Pemgarda |
| Genentech USA, INC. | $28.36 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $26.49 | 2021 | |
| Cormedix INC. | $22.02 | 2025 | Defencath |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.84 | 2023 | |
| Pfizer INC. | $21.31 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.93 | 2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $19.89 | 2025 | Keveyis |
| Insmed, INC. | $17.89 | 2024 | Arikayce |
| Horizon Therapeutics Plc | $16.26 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.23 | 2024 | Quviviq |
| Nabriva Therapeutics, Plc | $13.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Mayberry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.